Monti E, Sinha B K
Institute of Pharmacology, University of Milan, Italy.
Anticancer Res. 1994 May-Jun;14(3A):1221-6.
The effects of the combination of genistein, a tyrosine kinase inhibitor, and adriamycin, an anthracycline anticancer drug, were studied in three human breast carcinoma cell lines (MCF-7/WT, MCF-7/ADR(R) and MDA-231) differing in estrogen receptor status and adriamycin sensitivity. Genistein inhibited cell proliferation in all three cell lines (IC50 between 7.0 and 37.0 microM). The combination produced additive to synergistic effects; epidermal growth factor receptor modulation by adriamycin does not seem to be involved in this interaction. The possible therapeutic advantage of this drug combination, especially on hormone-independent and multidrug resistant tumor cells, deserves further investigation.
在三种雌激素受体状态和阿霉素敏感性不同的人乳腺癌细胞系（MCF-7/WT、MCF-7/ADR(R)和MDA-231）中研究了酪氨酸激酶抑制剂染料木黄酮与蒽环类抗癌药物阿霉素联合使用的效果。染料木黄酮在所有三种细胞系中均抑制细胞增殖（IC50在7.0至37.0微摩尔之间）。联合使用产生相加至协同效应；阿霉素对表皮生长因子受体的调节似乎不参与这种相互作用。这种药物联合使用可能具有的治疗优势，尤其是对激素非依赖性和多药耐药肿瘤细胞的优势，值得进一步研究。
